• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 12, 2016

View Archived Issues

Multi-dextrous Venclexta: Chronic lymphocytic leukemia win for Roche; Abbvie deals first hand for BCL-2

The FDA's accelerated go-ahead Monday for Venclexta, the first BCL-2 inhibitor to win market clearance, gave hope not only to patients with CLL with the 17p deletion but also to those with other cancers and to more companies that are developing drugs that target BCL-2. Read More

In the clinic

Aduro Biotech Inc., of Berkeley, Calif., said that during the upcoming American Association for Cancer Research meeting in New Orleans, its chief scientific officer, Thomas Dubensky will present an overview of a planned phase I trial to evaluate the safety, tolerability and possible anti-tumor activity of ADU-S100 given by intratumoral injection to patients with advanced cutaneously accessible solid tumors or lymphomas. Read More

Other news to note

Valeant Pharmaceuticals International Inc., of Laval, Quebec, issued a statement Monday that its board has requested CEO J. Michael Pearson to cooperate in connection with a subpoena for deposition from the Senate Committee on Aging prior to the schedule April 27 hearing. Read More

Earnings

Insys Therapeutics Inc., of Phoenix, is estimating its preliminary revenues from Subsys (fentanyl sublingual spray) for the first quarter will be in the range of $61 million to $62 million, which reflects a decline in demand. Read More

Downsizing abets brigatinib launch prospects as Ariad advances toward NDA

Despite a reduction in force two weeks ago at Ariad Pharmaceuticals Inc. that slashed 90 positions in the U.S. and Europe, the Cambridge, Mass.-based company moved brigatinib into its first phase III trial. Read More

Biocon gains key toehold in Japan with glargine approval

NEW DELHI – Taking another step toward international expansion, Indian pharma major Biocon Ltd. has secured its first approval in Japan for its biosimilar insulin glargine. Read More

GW broadens Epidiolex phase III work in third rare epilepsy indication

Following a positive readout last month for a phase III trial in Dravet syndrome, GW Pharmaceuticals plc is keeping the momentum going, launching late-stage testing of Epidiolex in another rare epilepsy indication and looking ahead to what could be an exciting 2016 for the London-based firm as cannabinoid-based platforms appear finally to be catching on. Read More

Medicare Part B reimbursement: Chicken Little or status quo?

Big changes are afoot in how Medicare reimburses for Part B drugs, and the reaction to the potential changes has stakeholders scurrying in every direction. Read More

Korea's Hanmi invests $200M in China-based manufacturing plant

HONG KONG – Taking another step to strengthen its presence in the promising Chinese market, South Korea-based Hanmi Science Co. Ltd. (KS:008930) will pour about $200 million into a new plant in the fast growing neighboring market. Read More

Resilience, methods to study causes, exists for Mendelian disorders

Resilience, the ability to thrive in spite of adversity, has long been a well-studied concept in psychological science. Read More

Financings

Viamet Pharmaceuticals Holdings LLC, of Durham, N.C., which filed for a $75 million IPO in 2014 but withdrew the registration a few months later, is making a second attempt to join the public ranks. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • Molecule illustration

    Unnatural Products joins Argenx in a $1.5B macrocyclic deal

    BioWorld
    Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • CMS logo and website

    CMS eyes competitive bidding for CGMs, insulin pumps

    BioWorld MedTech
    The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe